| 17264-54-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 17264-54-9
• 化学式: C8H8NaO2
• 分子量: 159.14
• InChiKey: OEZIHVUTMINADI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHOD FOR PRODUCING A RUTHENIUM COMPLEX
  申请人：Nara Hideki

  公开号：US20100076210A1

  公开（公告）日：2010-03-25

  Provided is a method for producing a ruthenium complex comprises the step of reacting a ruthenium compound represented by general formula (1): [RuX(L)(PP)]X   (1), wherein Ru represents a ruthenium atom; X represents a halogen atom; L represents an arene; and PP represents an optically active bisphosphine, with a carboxylate salt represented by general formula (2): R 1 CO 2 M   (2), wherein M represents a monovalent cation; and R 1 represents a group selected from the group consisting of alkyl groups, haloalkyl groups, phenyl groups optionally having a substituent(s), 1-aminoalkyl groups and 1-amino-1-phenylalkyl groups, to produce a ruthenium complex represented by general formula (3): Ru(OCOR 1 ) 2 (PP)   (3), wherein R 1 represents the group selected from the group consisting of alkyl groups, haloalkyl groups, phenyl groups optionally having a substituent(s), 1-aminoalkyl groups and 1-amino-1-phenylalkyl groups; and PP represents the optically active bisphosphine.

  提供的是一种制备钌配合物的方法，包括以下步骤：将由通式（1）表示的钌化合物与由通式（2）表示的羧酸盐反应，其中通式（1）为：[RuX(L)(PP)]X，其中Ru代表钌原子；X代表卤素原子；L代表芳烃；PP代表光学活性双膦；通式（2）为：R1CO2M，其中M代表一价阳离子；R1代表从烷基、卤代烷基、苯基（可选地带有取代基）、1-氨基烷基和1-氨基-1-苯基烷基组成的群中选择的基团，以制备由通式（3）表示的钌配合物：Ru(OCOR1)2(PP)，其中R1代表从烷基、卤代烷基、苯基（可选地带有取代基）、1-氨基烷基和1-氨基-1-苯基烷基组成的群中选择的基团；PP代表光学活性双膦。
• Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
  申请人：Partridge Joseph John

  公开号：US20070032535A1

  公开（公告）日：2007-02-08

  Disclosed is a method for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof, such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via dynamic kinetic resolutions.

  本发明公开了一种通过动态动力学分辨法制备(+)-(2S,3S)-2-(3-氯苯基)-3,5,5-三甲基-2-吗啉醇、制药可接受的盐以及制药可接受的溶剂化物的方法，例如通过动态动力学分辨法制备(+)-(2S,3S)-2-(3-氯苯基)-3,5,5-三甲基-2-吗啉醇盐酸盐。
• Ruthenium-phosphine complexes
  申请人：Takasago Perfumery Co., Ltd.

  公开号：EP0245959A2

  公开（公告）日：1987-11-19

  A ruthenium-phosphine complex having a 2,2ʹ-bis(diphenylphosphino)-1,1ʹ-binaphthyl or its derivative as a ligand and carboxyl groups bonded to the ruthenium atom is of the formula: where X is H an amino, acetylamino or sulfo group; R is a H or Cl-4 alkyl; R₁ and R₂ each is a Cl-9 alkyl, halogenated Cl-4 alkyl, phenyl, phenyl substituted with Cl-4 alkyl, Cl-4 α-aminoalkyl, or a C7-10 α-aminophenylalkyl group, or R₁ and R₂ together form a Cl-4 alkylene group; and n is 1 or 2. 17 specific complexes are disclosed. Synthesis is by treatment of a complex wherein the portion outside the bracket is Ru₂Cl₄ . N(C₂H₅)₃ with a carboxylic acid salt.

  以 2,2ʹ-双(二苯基膦)-1,1ʹ-联萘或其衍生物为配体、羧基键合于钌原子的钌膦络合物的结构式为 其中 X 为 H、氨基、乙酰氨基或磺基；R 为 H 或 Cl-4 烷基；R₁ 和 R₂ 各为 Cl-9 烷基、卤代 Cl-4 烷基、苯基、被 Cl-4 烷基取代的苯基、Cl-4 α-氨基烷基或 C7-10 α-氨基苯基烷基，或 R₁ 和 R₂ 共同形成 Cl-4 亚烷基；n 为 1 或 2。 公开了 17 种特定的配合物。 合成方法是处理络合物，其中括号外的部分是 Ru₂Cl₄。N(C₂H₅)₃的羧酸盐。
• Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors
  申请人：RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY

  公开号：EP0558245A1

  公开（公告）日：1993-09-01

  There are disclosed compounds of the general formula The heteroatom X is preferably oxygen, but may have other values. The group W is preferably a carbonyl group, but may have other values. The preferred heterocyclic ring is thus a 4-oxo-4H-1-benzopyran ring. This may have a wide range of R₂, R₃, R₆ and R₇ substituents. Y is a linking group, chosen from a wide range, but including -COO- , -CONH- , -O- , -SO₂- and -SO₂NH-. Z is an alkylene chain, and B is a complex amine. These compounds and their prodrugs, enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts are useful for the treatment of hypertension and urinary tract troubles associated with benign prostatic hypertrophy, and for the treatment of other diseases.

  已公开的化合物通式如下 杂原子 X 最好是氧，但也可以有其他值。基团 W 最好是羰基，但也可以有其他值。因此，优选的杂环是 4-氧代-4H-1-苯并吡喃环。它可以有多种 R₂、R₃、R₆ 和 R₇ 取代基。Y 是连接基团，可选范围很广，但包括-COO-、-CONH-、-O-、-SO₂- 和-SO₂NH-。Z 是亚烷基链，B 是复合胺。这些化合物及其原药、对映体、非对映异构体、N-氧化物和药学上可接受的盐类可用于治疗与良性前列腺肥大相关的高血压和尿路问题，也可用于治疗其他疾病。
• SURFACE MODIFIED FINE SILICA POWDER AND USE THEREOF
  申请人：Nippon Aerosil Co., Ltd.

  公开号：EP1262455A1

  公开（公告）日：2002-12-04

  The surface-modified fine silica powder of the present invention has the excellent effect as the mixing material of the printing material. When said fine silica powder is mixed to use for the ink acceptor layer, there are no blotting with ink and cracking of coating film etc., and the excellent printing effect can be obtained. Specifically, in the printing by the ink-jet, there is no blotting with ink, and excellent clear nature and fixing of ink are obtained.

  本发明的表面改性硅微粉作为印刷材料的混合材料，具有极佳的效果。当所述细硅石粉末混合后用于油墨接受层时，不会出现油墨沾污和涂膜开裂等现象，可获得极佳的印刷效果。具体而言，在喷墨印刷中，不会出现油墨吸墨现象，可获得极佳的清晰度和油墨固定性。